Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Frederick L. Locke(Moffitt Cancer Center), Jérôme Galon(Délégation Paris 5), Armando López‐Guillermo(Barcelona Supercomputing Center), Catherine J. Lee(University of Utah), Marco Schupp(Amgen (Switzerland)), Hildegard Greinix(Medical University of Graz), Mike Mattie, Simone Filosto(Kite (United States)), Gayatri Tiwari, Justin A. Budka(Gilead Sciences (United Kingdom)), Francesco M. Marincola(Center for Translational Molecular Medicine), Régis Perbost, Adrian Bot(Unknown), Saran Vardhanabhuti, Davide Bedognetti(Sidra Medical and Research Center), Rhine R. Shen(Broad Institute), Christina To, Peter Dreger(Heidelberg University), Paul Cheng(Cardiovascular Institute of the South), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Wangshu Zhang, Justin Chou, Nicolaus Kröger(Universität Hamburg), Harry Miao(Takeda (United States)), Brian T. Hill(Cleveland Clinic)
Cited by 114
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k